塞利尼索治疗多药耐药的中枢神经系统复发的弥漫大B细胞淋巴瘤1例并文献复习  

Selinexor treatment for diffuse large B-cell lymphoma with multidrug-resistant central nervous system recurrence:a case report and literature review

作　　者：张鸿雁 吴弘英[1] 于淑媛 钟玉萍[1] ZHANG Hongyan;WU Hongying;YU Shuyuan;ZHONG Yuping(Department of Hematology,Qingdao Municipal Hospital,Qingdao,266071,China)

机构地区：[1]康复大学青岛医院(青岛市市立医院)血液科,山东青岛266071

出　　处：《临床血液学杂志》2023年第11期828-830,834,共4页Journal of Clinical Hematology

摘　　要：弥漫大B细胞淋巴瘤是一种来源于成熟B细胞的侵袭性肿瘤,是最常见的非霍奇金淋巴瘤类型,占全部非霍奇金淋巴瘤的25%~50%。尽管一线治疗有效率50%以上,但仍有部分患者复发后生存期短。塞利尼索是全球首款选择性核输出蛋白抑制剂,选择性作用于XPO1靶点,已被批准用于复发难治多发性骨髓瘤、弥漫大B细胞淋巴瘤的治疗。我中心应用塞利尼索治疗1例多药耐药中枢复发的弥漫大B细胞淋巴瘤患者,该患者经一线治疗疾病完全缓解后出现中枢神经系统复发,经多线治疗后疾病仍进展且呈现多药耐药,给予其塞利尼索挽救治疗。现将患者治疗后的疗效和生存情况进行总结。Diffuse large B-cell lymphoma(DLBCL)is an aggressive tumor derived from mature B cells and is the most common type of non-Hodgkin lymphoma,accounting for about 25%-50%of all non-Hodgkin lymphoma.Although the response rate of first-line therapy is more than 50%,some patients will have short survival after relapse.Selinexor is the world's first selective nuclear export inhibitor,which selectively binds to the XPO1 target and has been approved for the treatment of relapsed and refractory multiple myeloma and DLBCL.We recently used selinexor to the treatment of a patient with multidrug-resistant and central nervous recurrent DLBCL.The patient experienced central nervous system recurrence after complete remission from the first-line treatment.The disease still progressed and showed multidrug resistance through multi-line treatments.The patient received selinexor as the salvage therapy.Here is a summary of the patient's efficacy and survival after treatment.

关 键 词：塞利尼索 弥漫大B细胞淋巴瘤 中枢神经系统复发 

分 类 号：R733.4[医药卫生—肿瘤]